{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:22:33Z","timestamp":1784823753632,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Broadly neutralizing antibodies (bNAbs) are a promising treatment option for children with HIV-1, but their long-term impact on virologic, immunologic, and clinical outcomes is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Tatelo Study investigated dual bNAbs as an alternative to standard antiretroviral treatment (ART) in children. Children received bNAb-only treatment for 24 weeks (or until detectable viremia \u2265400\u2005copies\/mL occurred) and were followed initially through 24 weeks after restarting ART. We continued follow-up from 24 to 96 weeks post-bNAb intervention to identify the long-term clinical, immunologic, and viral reservoir outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age at the start of long-term follow-up was 4.9 years (range 3.4, 6.8 years). From 23.0 to 43.6 weeks post-bNAb intervention, all 25 children transitioned to dolutegravir-based ART; 3 (12%) had a single episode of HIV-1 RNA \u2265 40\u2005copies\/mL after starting the DTG-based regimen and re-suppressed with adherence counseling on the same regimen. There were no grade 3 or 4 events, and no child died. Absolute CD4 cell counts remained stable at 96 weeks post-bNAb intervention (median: 1130\u2005cells\/mm3, IQR: 840, 1249\u2005cells\/mm3), and clinical biomarkers (serology, qualitative HIV DNA) were stable. At last available sampling, only 8 (32%) participants had detectable intact provirus (5 had rebounded during the bNAb-only intervention phase), with a low median HIV-1 DNA in PBMCs of 0.39 log10 (range 0.1 to 3.8 log10) copies\/106 cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was no long-term impact on safety, clinical, immunologic, or virologic outcomes after bNAb-only treatment, including for children who rebounded during the intervention. These findings support further bNAb treatment trials in children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov, NCT03707977, https:\/\/clinicaltrials.gov\/.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf568","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:16:15Z","timestamp":1760012175000},"page":"e278-e285","source":"Crossref","is-referenced-by-count":4,"title":["Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5408-4823","authenticated-orcid":false,"given":"Gbolahan","family":"Ajibola","sequence":"first","affiliation":[{"name":"Botswana Harvard Health Partnership , Gaborone ,","place":["Botswana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4964-067X","authenticated-orcid":false,"given":"Bryan S","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aischa","family":"Niesar","sequence":"additional","affiliation":[{"name":"Ragon Institute of Massachusetts General Hospital, MIT, and Harvard , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seohyun","family":"Hong","sequence":"additional","affiliation":[{"name":"Ragon Institute of Massachusetts General Hospital, MIT, and Harvard , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3777-0271","authenticated-orcid":false,"given":"Melanie","family":"Lancien","sequence":"additional","affiliation":[{"name":"Ragon Institute of Massachusetts General Hospital, MIT, and Harvard , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-2376","authenticated-orcid":false,"given":"Molly Pretorius","family":"Holme","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-1004","authenticated-orcid":false,"given":"Dwight E","family":"Yin","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Jean-Philippe","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3821-4592","authenticated-orcid":false,"given":"Sikhulile","family":"Moyo","sequence":"additional","affiliation":[{"name":"Botswana Harvard Health Partnership , Gaborone ,","place":["Botswana"]},{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Pathology, Division of Medical Virology, Stellenbosch University , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oganne","family":"Batlang","sequence":"additional","affiliation":[{"name":"Botswana Harvard Health Partnership , Gaborone ,","place":["Botswana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Sakoi","sequence":"additional","affiliation":[{"name":"Botswana Harvard Health Partnership , Gaborone ,","place":["Botswana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Comfort","family":"Maphorisa","sequence":"additional","affiliation":[{"name":"Botswana Harvard Health Partnership , Gaborone ,","place":["Botswana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Botswana Harvard Health Partnership , Gaborone ,","place":["Botswana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5384-9716","authenticated-orcid":false,"given":"Shahin","family":"Lockman","sequence":"additional","affiliation":[{"name":"Botswana Harvard Health Partnership , Gaborone ,","place":["Botswana"]},{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0017-2438","authenticated-orcid":false,"given":"Joseph","family":"Makhema","sequence":"additional","affiliation":[{"name":"Botswana Harvard Health Partnership , Gaborone ,","place":["Botswana"]},{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R","family":"Kuritzkes","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Lichterfeld","sequence":"additional","affiliation":[{"name":"Ragon Institute of Massachusetts General Hospital, MIT, and Harvard , Cambridge, Massachusetts ,","place":["USA"]},{"name":"Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger L","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Botswana Harvard Health Partnership , Gaborone ,","place":["Botswana"]},{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2026031306483098500_ciaf568-B1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"2026031306483098500_ciaf568-B2","doi-asserted-by":"crossref","first-page":"eadh0004","DOI":"10.1126\/scitranslmed.adh0004","article-title":"Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana","volume":"15","author":"Shapiro","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026031306483098500_ciaf568-B3","first-page":"23","article-title":"Clinical non-adherence and its associated factors among HIV-positive pediatric patients attending HIV care in South Gondar Zone Public Health Facilities, Northwest Ethiopia, 2021","volume":"14","author":"Tiruneh","year":"2022","journal-title":"HIV AIDS (Auckl)"},{"key":"2026031306483098500_ciaf568-B4","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/cid\/cix194","article-title":"Optimizing research to speed up availability of pediatric antiretroviral drugs and formulations","volume":"64","author":"Penazzato","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026031306483098500_ciaf568-B5","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1016\/S2352-3018(22)00101-1","article-title":"Advancing the prevention and treatment of HIV in children: priorities for research and development","volume":"9","author":"Penazzato","year":"2022","journal-title":"Lancet HIV"},{"key":"2026031306483098500_ciaf568-B6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11904-021-00569-8","article-title":"Analytical treatment interruption in HIV trials: statistical and study design considerations","volume":"18","author":"Zheng","year":"2021","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2026031306483098500_ciaf568-B7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/QAI.0000000000003033","article-title":"Safety and pharmacokinetics of intravenous 10-1074 and VRC01LS in young children","volume":"91","author":"Capparelli","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031306483098500_ciaf568-B8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/cid\/ciaa028","article-title":"Safety and efficacy of starting antiretroviral therapy in the first week of life","volume":"72","author":"Maswabi","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"2026031306483098500_ciaf568-B9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/QAI.0000000000003147","article-title":"Brief report: long-term clinical, immunologic, and virologic outcomes among early-treated children with HIV in Botswana: a nonrandomized controlled clinical trial","volume":"92","author":"Ajibola","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031306483098500_ciaf568-B10","volume-title":"Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, version 2.0","author":"US Department of Health and Human Services","year":"2017"},{"key":"2026031306483098500_ciaf568-B11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nm.3445","article-title":"HIV-1 persistence in CD4+ T cells with stem cell-like properties","volume":"20","author":"Buzon","year":"2014","journal-title":"Nat Med"},{"key":"2026031306483098500_ciaf568-B12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-1-0716-1871-4_23","article-title":"Near-full-length single-genome HIV-1 DNA sequencing","volume":"2407","author":"Lee","year":"2022","journal-title":"Methods Mol Biol"},{"key":"2026031306483098500_ciaf568-B13","doi-asserted-by":"crossref","first-page":"eaax7350","DOI":"10.1126\/scitranslmed.aax7350","article-title":"Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile","volume":"11","author":"Garcia-Broncano","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026031306483098500_ciaf568-B14","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1172\/JCI124291","article-title":"Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy","volume":"129","author":"Einkauf","year":"2019","journal-title":"J Clin Invest"},{"key":"2026031306483098500_ciaf568-B15","author":"Thomas"},{"key":"2026031306483098500_ciaf568-B16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.inf.0000168835.01233.64","article-title":"Age-related standards for total lymphocyte, CD4+ and CD8+ T cell counts in children born in Europe","volume":"24","author":"Study","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"2026031306483098500_ciaf568-B17","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1128\/CVI.00483-10","article-title":"Reference values of lymphocyte subsets in healthy, HIV-negative children in Cameroon","volume":"18","author":"Sagnia","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"2026031306483098500_ciaf568-B18","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000003663","article-title":"Predictive markers for sustained viral suppression on dual bNAbs during ART interruption in children","author":"Banga","year":"2025","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031306483098500_ciaf568-B19","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3390\/biomedicines12092083","article-title":"Evaluation of viral suppression in paediatric populations: implications for the transition to dolutegravir-based regimens in Cameroon: the CIPHER-ADOLA study","volume":"12","author":"Fokam","year":"2024","journal-title":"Biomedicines"},{"key":"2026031306483098500_ciaf568-B20","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1186\/s12887-024-05295-9","article-title":"Viral load suppression and retention in care among children and adolescents receiving multi-month anti-retroviral therapy refills: a program data review in Uganda","volume":"24","author":"Ainembabazi","year":"2024","journal-title":"BMC Pediatr"},{"key":"2026031306483098500_ciaf568-B21","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3018(21)00265-4","article-title":"Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries","volume":"8","author":"Han","year":"2021","journal-title":"Lancet HIV"},{"key":"2026031306483098500_ciaf568-B22","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciad626","article-title":"Evolution of CD4 T-cell count with age in a cohort of young people growing up with perinatally acquired human immunodeficiency virus","volume":"78","author":"Castro","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026031306483098500_ciaf568-B23","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3389\/fimmu.2017.01162","article-title":"Thymic output and CD4 T-cell reconstitution in HIV-infected children on early and interrupted antiretroviral treatment: evidence from the children with HIV early antiretroviral therapy trial","volume":"8","author":"Lewis","year":"2017","journal-title":"Front Immunol"},{"key":"2026031306483098500_ciaf568-B24","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/QAI.0000000000002905","article-title":"Quantification of CD4 recovery in early-treated infants living with HIV","volume":"89","author":"Schr\u00f6ter","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031306483098500_ciaf568-B25","doi-asserted-by":"crossref","first-page":"e1013003","DOI":"10.1371\/journal.ppat.1013003","article-title":"Intact HIV DNA decays in children with and without complete viral load suppression","volume":"21","author":"Reeves","year":"2025","journal-title":"PLoS Pathog"},{"key":"2026031306483098500_ciaf568-B26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"2026031306483098500_ciaf568-B27","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2352-3018(23)00236-9","article-title":"HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1\/2 proof-of-concept study","volume":"11","author":"Persaud","year":"2024","journal-title":"Lancet HIV"},{"key":"2026031306483098500_ciaf568-B28","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nature17642","article-title":"Corrigendum: viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"535","author":"Caskey","year":"2016","journal-title":"Nature"},{"key":"2026031306483098500_ciaf568-B29","doi-asserted-by":"crossref","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf568\/64655833\/ciaf568.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/2\/e278\/64655833\/ciaf568.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/2\/e278\/64655833\/ciaf568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:48:39Z","timestamp":1773398919000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/2\/e278\/8284746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,13]]},"published-print":{"date-parts":[[2026,2,25]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf568","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,15]]},"published":{"date-parts":[[2025,10,13]]}}}